Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase-Reference-Cited by-同舟云学术

Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

Published:2019-10-25 Issue:5 Volume:61 Page:689-695
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Rathke Hendrik,Holland-Letz Tim,Mier Walter,Flechsig Paul,Mavriopoulou Eleni,Röhrich Manuel,Kopka Klaus,Hohenfellner Markus,Giesel Frederik Lars,Haberkorn Uwe,Kratochwil Clemens

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference31 articles.

1. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

2. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

3. Radionuclide therapy of metastatic prostate cancer;Kratochwil;Semin Nucl Med.,2019

4. Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes: Figure 1.

5. Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer;Cancer Letters;2024-08

2. Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-09

3. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05

4. Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival;Molecular Imaging and Biology;2024-02-15

5. Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy;Journal for ImmunoTherapy of Cancer;2023-10